Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy

1

Biliary tract cancer (BTC) has low 5-year survival rates, with surgical resection being the only curative option for early-stage disease.
2

Durvalumab, an anti-PD-L1 monoclonal antibody, has shown improved overall survival when combined with gemcitabine and cisplatin in advanced BTC.
3

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors can affect various organs and may correlate with better clinical outcomes.
4

This study aims to evaluate the prognostic role of imaging-detected irAEs in BTC patients treated with durvalumab-based chemotherapy.
5

The primary endpoint of the study is overall survival, with secondary endpoints including progression-free survival and treatment response.

1